Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 250 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 250 shares of the company’s stock in a transaction on Monday, October 14th. The shares were sold at an average price of $57.19, for a total value of $14,297.50. Following the completion of the sale, the vice president now directly owns 56,488 shares in the company, valued at $3,230,548.72. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Friday, September 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $56.82, for a total transaction of $14,205.00.
• On Tuesday, August 13th, Meredith Cook sold 250 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.62, for a total transaction of $14,905.00.

ANI Pharmaceuticals Price Performance

ANIP stock opened at $58.60 on Wednesday. The stock has a market capitalization of $1.23 billion, a price-to-earnings ratio of 36.63 and a beta of 0.71. The company has a quick ratio of 3.07, a current ratio of 3.97 and a debt-to-equity ratio of 0.62. ANI Pharmaceuticals, Inc. has a 52-week low of $48.20 and a 52-week high of $70.81. The stock’s fifty day simple moving average is $59.41 and its 200-day simple moving average is $62.55.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.95 by $0.07. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $138.00 million for the quarter, compared to analyst estimates of $129.09 million. During the same period last year, the company earned $1.06 EPS. The firm’s quarterly revenue was up 18.5% on a year-over-year basis. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ANIP. Truist Financial reissued a “hold” rating and set a $60.00 price objective (down from $80.00) on shares of ANI Pharmaceuticals in a research note on Wednesday, September 11th. Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They issued an “overweight” rating and a $68.00 price target for the company. Raymond James upped their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Finally, HC Wainwright restated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.00.

Institutional Investors Weigh In On ANI Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Innealta Capital LLC acquired a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at $65,000. Ridgewood Investments LLC purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth $85,000. SG Americas Securities LLC acquired a new position in ANI Pharmaceuticals in the first quarter valued at $106,000. O Shaughnessy Asset Management LLC purchased a new stake in ANI Pharmaceuticals during the first quarter valued at about $218,000. Finally, XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the second quarter worth about $207,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.